UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $100
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $100.
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $100.